The Serum Institute of India (SII) has submitted the data to DCGI’s Subject Expert Committee (SEC).In previous meeting by SEC Serum Institute of India and bharat biotech was asked to submit more data about clinical trials, reports IANS
The SEC can do a meeting on Serum Institute of India’s emergency authorisation for Covishield vaccine at the end of this week.
In recent years, India has made significant strides in the fight against cancer, with an…
As we age, our cognitive abilities naturally decline, but diet has emerged as a key…
In a significant move toward revolutionizing patient care, a panel discussion on Artificial Intelligence (AI)-based…
Breast cancer remains one of the leading causes of cancer-related deaths among women worldwide. Early…
Airport Proximity: Can living near an airport increase your risk of a heart attack? A…
Antimicrobial resistance (AMR), the ability of bacteria, fungi, and parasites to resist the effects of…